Información del artículo
El Texto completo está disponible en PDF
Bibliografía Recomendada
[American Diabetes Association, 2002]
American Diabetes Association.
Clinical Practice Recommendations 2002. Diabetes Care, 25 (2002), pp. s1-s147
[Brenner, et.al, 2001]
B.M. Brenner, M.E. Cooper, D. De Zeew, W.F. Keane, W.E. Mitch, H.H. Parving.
for the RENAAL Study Group. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.
N Engl J Med, 345 (2001), pp. 861-869
[1997]
Documento de Consenso sobre pautas de detección y tratamiento de la nefropatía diabética en España. Sociedades españolas de Diabetes, Endocrinología-Nutrición, Medicina Familiar y Comunitaria, Nefrología.
Nefrología, 17 (1997), pp. 467-474
[2000]
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes: results of the HOPE study and MICRO-HOPE substudy.
Lancet, 355 (2000), pp. 253-259
[Fioretto, et.al, 1998]
P. Fioretto, M.W. Steffes, D.E.R. Sutherland, F.C. Goetz, M. Mauer.
Reversal of lesions of diabetic nephropathy after pancreas transplantation.
N Engl J Med, 339 (1998), pp. 69-75
[Freeman, et.al, 2001]
D.J. Freeman, J. Norrie, N. Sattar, R.D. Neely, S.M. Cobbe, et al.
Pravastatin and the development of diabetes mellitus. Evidence for a Protective effect in the West Scotland Coronary Prevention Study.(WOSCOPS).
Circulation, 103 (2001), pp. 359-361
[1999]
Guidelines Subcommittee: 1999 World Health Organization-International Society of Hypertension Guidelines for the Management of Hypertension.
J Hypertension, 17 (1999), pp. 151-183
[Hansson, et.al, 1998]
L. Hansson, A. Zanchetti, S.G. Carruther, B. Dahlof, D. Elmfeldt, S. Julius.
Effects of intensive blood-presure lowering and low-dose aspirin in patients with hypertension. principal results of the Hypertension Optimal Treatment (HOT) randomised trial.
Lancet, 351 (1998), pp. 1755-1762
[2000]
Heart Outcomes Prevention Evaluations (HOPE) Study Investigators: effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE and MICROHOPE substudy.
Lancet, 355 (2000), pp. 253-259
[Lewis, et.al, 1993]
E.J. Lewis, I.G. Hunsincker, R.P. Bain.
Rhode RD and Collaborative Study Group. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.
N Engl J Med, 329 (1993), pp. 1456-1462
[E, et.al, 2001]
J Lewis E, L.G. Hunsicker, W. Clarke, T. berl, M.A. Pohl, J.B. Lewis.
for the Collaborative Study Group. Renoprotective effect of the angiotensinreceptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.
N Engl J Med, 345 (2001), pp. 851-860
[Parving, et.al, 2001]
H.H. Parving, H. Lehnert, J. Bröchner-Mortensen, R. Gomis, S. Anderson, P. Arner.
The effect of irbesartan on the development of diabetic nephropaty in patients with type-2.
N Engl J Med, 345 (2001), pp. 870-878
[Ravid, et.al, 1998]
M. Ravid, D. Bros, Z. Levi, Y. Bar-Dayan, D. Ravid, R. Rachmani.
Use of enalapril to atenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus.
Ann Intern Med, 128 (1998), pp. 982-988
[Ravid, et.al, 1993]
M. Ravid, H. Savin, I. Jutrin, T. Bental, B. Katz, M. Lishner.
Long-term stabilizing effect of angiotensing-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients.
Ann Intern Med, (1993), pp. 577-581
[Remuzzi, et.al, 2002]
G. Remuzzi, A. Schieppati, P. Ruggenenti.
Nephropathy in Patients with Type 2 diabetes.
N Engl J Med, 346 (2002), pp. 1141-1145
[Scheid, et.al, 2001]
D.C. Scheid, L.H. McCarthy, F.H. Lawler, R.M. Hamm, K.E.H. Reilly.
Screening for microalbuminuria to prevent nephropathy in patients with diabetes.
J Famlily Pract, 50 (2001), pp. 661-668
[1997]
The Joint National Committee on Prevention, Detection, Evaluation and Treatment of high blood pressure: The sixth report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of high blood pressure.
Arch Intern Med, 157 (1997), pp. 2413-2446
[UK Prospective Diabetes Study Group, 1998]
UK Prospective Diabetes Study Group.
Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes.UKPDS 39.
Br Med J, 317 (1998), pp. 713-720
[UK Prospective Diabetes Study Group, 1998]
UK Prospective Diabetes Study Group.
Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33).
Lancet, 325 (1998), pp. 837-853
Asociación Española de Nefrología Pediátrica (AEN-PED), Sociedad Española de Diabetes (SED), Sociedad Española de Endocrinología y Nutrición (SEEN), Sociedad Española de Hipertensión Arterial y Liga Española para la Lucha Contra la HTA (SEH-LELHA), Sociedad Española de Medicina Familiar y Comunitaria (SEMFYC), Sociedad Española de Medicina Rural y Generalista (SEMERGEN), Sociedad Española de Nefrología (SEN)
Copyright © 2002. Elsevier España, S.L. y Sociedad Española de Medicina Rural y Generalista (SEMERGEN)
